Table 2

Nichebuster orphan medicines with a revenue higher than €1bn in 2019.

ProductRevenue 2019 (€)
Revlimid10 790 457 540
Imbruvica*7 196 902 261
Soliris3 512 907 246
Darzalex2 668 684 351
Pomalyst/Imnovid2 534 270 963
Jakavi/Jakafi†2 491 426 781
Sprycel1 878 226 811
Spinraza1 866 654 798
Tasigna1 673 342 234
Ofev1 491 000 000
Xyrem1 462 101 656
Afinitor/Votubia1 366 266 133
Symkevi/Symdeko1 261 944 098
Revolade/Promacta1 260 347 130
Orkambi1 185 589 283
Opsumit1 181 235 535
Glivec1 124 165 554
Eloctate1 115 519 700
Lynparza1 066 405 555
Esbriet1 013 451 262
  • * Imbruvica is sold by Johnson & Johnson and AbbVie. †Jakavi/Jakafi is sold by Novartis and Incyte.